https://www.strobe-statement.org/index.php?id=available-checklists

STROBE Statement—Checklist of items that should be included in reports of ***cross-sectional studies***

Page		Item No	Recommendation
1-4	**Title and abstract**	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract
			(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found
	Introduction		
5-10	Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
5,6	Objectives	3	State specific objectives, including any prespecified hypotheses
	Methods		
10	Study design	4	Present key elements of study design early in the paper
11	Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
11	Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of selection of participants
11-12 and table 1	Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
11-13	Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
11 by the sampling technique and data collection steps and ethical consideration	Bias	9	Describe any efforts to address potential sources of bias
11	Study size	10	Explain how the study size was arrived at
11,12	Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
12,13	Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding
13: ANOVA			(*b*) Describe any methods used to examine subgroups and interactions
12			(*c*) Explain how missing data were addressed
NA			(*d*) If applicable, describe analytical methods taking account of sampling strategy
NA			(*e*) Describe any sensitivity analyses
	Results		
11,13,14	Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
NA			(b) Give reasons for non-participation at each stage
NA			(c) Consider use of a flow diagram
13-15	Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential

			confounders
Tables especially table 1			(b) Indicate number of participants with missing data for each variable of interest
Tables 1-4	Outcome data	15*	Report numbers of outcome events or summary measures
Tables 1-4	Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included
NA			(*b*) Report category boundaries when continuous variables were categorized
NA			(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Tables 4	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
	Discussion		
13-21	Key results	18	Summarise key results with reference to study objectives
26-27	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
22-26	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
26-27	Generalisability	21	Discuss the generalisability (external validity) of the study results
	Other information		
NA	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.